Medivolve Inc. (MEDVF)
USD 0.01
(133.33%)
USD 0.01
(133.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.11 Million CAD | -85.32% |
| 2022 | 26.89 Million CAD | 17.67% |
| 2021 | 22.85 Million CAD | 73.74% |
| 2020 | 13.15 Million CAD | 442.68% |
| 2019 | 2.42 Million CAD | 140.49% |
| 2018 | 1 Million CAD | -74.77% |
| 2017 | 3.99 Million CAD | 278.1% |
| 2016 | 1.05 Million CAD | 6.83% |
| 2015 | 989.23 Thousand CAD | -49.07% |
| 2014 | 1.94 Million CAD | 11.47% |
| 2013 | 1.74 Million CAD | 2.63% |
| 2012 | 1.69 Million CAD | -18.41% |
| 2011 | 2.08 Million CAD | 0.08% |
| 2010 | 2.07 Million CAD | 14.74% |
| 2009 | 1.81 Million CAD | 42.4% |
| 2008 | 1.27 Million CAD | 778.36% |
| 2007 | 144.87 Thousand CAD | 7.73% |
| 2006 | 134.47 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 729.96 Thousand CAD | 13.07% |
| 2023 Q3 | 1.29 Million CAD | -50.75% |
| 2023 FY | 3.94 Million CAD | -85.32% |
| 2023 Q4 | 764.41 Thousand CAD | -40.89% |
| 2023 Q1 | 3 Million CAD | 219.28% |
| 2023 Q2 | 2.62 Million CAD | -12.54% |
| 2022 Q4 | -2.51 Million CAD | -130.46% |
| 2022 Q3 | 8.26 Million CAD | -9.97% |
| 2022 Q2 | 9.17 Million CAD | 13.35% |
| 2022 FY | 26.89 Million CAD | 17.67% |
| 2022 Q1 | 8.09 Million CAD | 104.14% |
| 2021 FY | 22.85 Million CAD | 73.74% |
| 2021 Q1 | 10.07 Million CAD | 38.17% |
| 2021 Q2 | 4.97 Million CAD | -50.59% |
| 2021 Q3 | 3.65 Million CAD | -26.66% |
| 2021 Q4 | 3.96 Million CAD | 8.66% |
| 2020 Q4 | 7.29 Million CAD | 234.32% |
| 2020 FY | 13.15 Million CAD | 442.68% |
| 2020 Q1 | 1.16 Million CAD | 67.33% |
| 2020 Q2 | 2.51 Million CAD | 116.24% |
| 2020 Q3 | 2.18 Million CAD | -13.44% |
| 2019 Q3 | 552.84 Thousand CAD | -32.46% |
| 2019 FY | 2.42 Million CAD | 140.49% |
| 2019 Q1 | 356.64 Thousand CAD | 5.36% |
| 2019 Q2 | 818.58 Thousand CAD | 129.53% |
| 2019 Q4 | 696.29 Thousand CAD | 25.95% |
| 2018 Q4 | 338.48 Thousand CAD | 39.88% |
| 2018 Q3 | 241.98 Thousand CAD | 30.94% |
| 2018 Q2 | 184.81 Thousand CAD | -23.89% |
| 2018 FY | 1 Million CAD | -74.77% |
| 2018 Q1 | 242.81 Thousand CAD | -91.93% |
| 2017 Q4 | 3.01 Million CAD | 776.82% |
| 2017 FY | 3.99 Million CAD | 278.1% |
| 2017 Q3 | 343.29 Thousand CAD | 19.0% |
| 2017 Q2 | 288.48 Thousand CAD | -18.47% |
| 2017 Q1 | 353.82 Thousand CAD | -57.99% |
| 2016 Q3 | -74.82 Thousand CAD | -150.48% |
| 2016 Q2 | 148.22 Thousand CAD | 5.04% |
| 2016 Q1 | 141.11 Thousand CAD | -37.52% |
| 2016 FY | 1.05 Million CAD | 6.83% |
| 2016 Q4 | 842.26 Thousand CAD | 1225.65% |
| 2015 FY | 989.23 Thousand CAD | -49.07% |
| 2015 Q4 | 225.85 Thousand CAD | -9.41% |
| 2015 Q3 | 249.32 Thousand CAD | 6.04% |
| 2015 Q2 | 235.13 Thousand CAD | -15.7% |
| 2015 Q1 | 278.91 Thousand CAD | -51.97% |
| 2014 Q2 | 680.44 Thousand CAD | 85.87% |
| 2014 Q1 | 366.08 Thousand CAD | -23.78% |
| 2014 Q3 | 315.18 Thousand CAD | -53.68% |
| 2014 FY | 1.94 Million CAD | 11.47% |
| 2014 Q4 | 580.68 Thousand CAD | 84.24% |
| 2013 Q3 | 434.21 Thousand CAD | 2.73% |
| 2013 Q1 | 405.31 Thousand CAD | -4.22% |
| 2013 Q2 | 422.66 Thousand CAD | 4.28% |
| 2013 Q4 | 480.27 Thousand CAD | 10.61% |
| 2013 FY | 1.74 Million CAD | 2.63% |
| 2012 FY | 1.69 Million CAD | -18.41% |
| 2012 Q4 | 423.16 Thousand CAD | -1.83% |
| 2012 Q3 | 431.03 Thousand CAD | 18.16% |
| 2012 Q2 | 364.78 Thousand CAD | -23.56% |
| 2012 Q1 | 477.2 Thousand CAD | 7.58% |
| 2011 Q3 | 248.51 Thousand CAD | -75.49% |
| 2011 Q1 | 375.03 Thousand CAD | -14.43% |
| 2011 FY | 2.08 Million CAD | 0.08% |
| 2011 Q2 | 1.01 Million CAD | 170.3% |
| 2011 Q4 | 443.58 Thousand CAD | 78.5% |
| 2010 Q4 | 438.29 Thousand CAD | 8.8% |
| 2010 Q3 | 402.85 Thousand CAD | -34.81% |
| 2010 Q2 | 617.97 Thousand CAD | -0.33% |
| 2010 FY | 2.07 Million CAD | 14.74% |
| 2010 Q1 | 620.02 Thousand CAD | 92.2% |
| 2009 Q2 | 291.98 Thousand CAD | -10.63% |
| 2009 FY | 1.81 Million CAD | 42.4% |
| 2009 Q3 | 870.71 Thousand CAD | 198.21% |
| 2009 Q1 | 326.71 Thousand CAD | 125.04% |
| 2009 Q4 | 322.59 Thousand CAD | -62.95% |
| 2008 Q1 | 55.49 Thousand CAD | -44.56% |
| 2008 Q4 | -1.3 Million CAD | -158.58% |
| 2008 Q3 | 2.22 Million CAD | 657.05% |
| 2008 FY | 1.27 Million CAD | 778.36% |
| 2008 Q2 | 294.27 Thousand CAD | 430.24% |
| 2007 Q1 | 5377.00 CAD | -24.95% |
| 2007 Q3 | 39.17 Thousand CAD | 18205.61% |
| 2007 Q4 | 100.1 Thousand CAD | 155.55% |
| 2007 Q2 | 214.00 CAD | -96.02% |
| 2007 FY | 144.87 Thousand CAD | 7.73% |
| 2006 FY | 134.47 Thousand CAD | 0.0% |
| 2006 Q2 | 54.84 Thousand CAD | 29.41% |
| 2006 Q4 | 7165.00 CAD | -76.18% |
| 2006 Q1 | 42.38 Thousand CAD | 0.0% |
| 2006 Q3 | 30.08 Thousand CAD | -45.16% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -292.494% |
| Arrayit Corporation | 6.19 Million USD | 33.567% |
| Atlantic International Corp. | 5.57 Million USD | 26.191% |
| Biocept, Inc. | 29.4 Million USD | 85.996% |
| Bioqual, Inc. | 7.44 Million USD | 44.726% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -433.226% |
| DermTech, Inc. | 104.01 Million USD | 96.042% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 97.527% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 81.801% |
| iMD Companies, Inc. | 151.8 Thousand USD | -2612.132% |
| IDenta Corp. | 662.97 Thousand USD | -521.028% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 79.65% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -10489.391% |
| InVitro International | 661.32 Thousand USD | -522.578% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 41.994% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -6985.044% |
| Medical Imaging Corp. | 1.91 Million USD | -115.319% |
| NovelStem International Corp. | 3.53 Million USD | -16.379% |
| Optigenex Inc. | 1.28 Million USD | -219.696% |
| PharmChem, Inc. | 2.93 Million USD | -40.462% |
| Proteome Sciences plc | 3.26 Million USD | -25.987% |
| Response Genetics, Inc | 25.31 Million USD | 83.738% |
| Rennova Health, Inc. | 7.67 Million USD | 46.374% |
| RushNet, Inc. | 1.78 Million USD | -130.102% |
| ScreenPro Security Inc. | 3.23 Million USD | -27.119% |
| Stella Diagnostics Inc. | 11.42 Million USD | 63.969% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 43.93% |
| Todos Medical Ltd. | 14.05 Million USD | 70.712% |